Extended-spectrum β-lactamase-producing organisms

Journal of Hospital Infection

Volumn 73, Issue 4, 2009, Pages 345-354

  Falagas, M E ^a,b,c   Karageorgopoulos, D E ^a  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFEPIME; CEFMETAZOLE; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFPODOXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CEPHAMYCIN; CILASTATIN; CLAVULANIC ACID; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; FLOMOXEF; FOSFOMYCIN; IMIPENEM; LATAMOXEF; PENICILLIN G; POLYMYXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TIGECYCLINE; UNINDEXED DRUG;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CLINICAL TRIAL; DRUG HYDROLYSIS; DRUG USE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; HOSPITAL INFECTION; HOSPITAL PERSONNEL; HOSPITALIZATION; HUMAN; IN VITRO STUDY; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE; MEDICAL INSTRUMENTATION; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; CROSS INFECTION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 71549169890     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhin.2009.02.021     Document Type: Review

References (52)

1. Bush K., Jacoby G.A., and Medeiros A.A. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 39 (1995) 1211-1233
2. Ambler R.P., and Meadway R.J. Chemical structure of bacterial penicillinases. Nature 222 (1969) 24-26
3. Jacoby G.A., and Munoz-Price L.S. The new beta-lactamases. N Engl J Med 352 (2005) 380-391
4. Jones C.H., Tuckman M., Keeney D., Ruzin A., and Bradford P.A. Characterization and sequence analysis of extended spectrum β-lactamase encoding genes from Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. Antimicrob Agents Chemother 53 (2009) 465-475
5. Livermore D.M., Canton R., Gniadkowski M., et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 59 (2007) 165-174
6. Bonnet R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 48 (2004) 1-14
7. Reinert R.R., Low D.E., Rossi F., Zhang X., Wattal C., and Dowzicky M.J. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 60 (2007) 1018-1029
8. Hackel M, Badal R, Bouchillon S, et al. Extended-spectrum beta-lactamase production in Europe. In: Abstracts of the 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona, Spain, 2008.
9. Pitout J.D., and Laupland K.B. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8 (2008) 159-166
10. Lewis II J.S., Herrera M., Wickes B., Patterson J.E., and Jorgensen J.H. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother 51 (2007) 4015-4021
11. Drieux L., Brossier F., Sougakoff W., and Jarlier V. Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide. Clin Microbiol Infect 14 Suppl. 1 (2008) 90-103
12. Wiegand I., Geiss H.K., Mack D., Sturenburg E., and Seifert H. Detection of extended-spectrum beta-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures. J Clin Microbiol 45 (2007) 1167-1174
13. Rodriguez-Bano J., Alcala J.C., Cisneros J.M., et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 168 (2008) 1897-1902
14. Paterson D.L., and Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18 (2005) 657-686
15. Canton R., Novais A., Valverde A., et al. Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect 14 Suppl. 1 (2008) 144-153
16. Rodriguez-Bano J., Lopez-Cerero L., Navarro M.D., Diaz de Alba P., and Pascual A. Faecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. J Antimicrob Chemother 62 (2008) 1142-1149
17. Falagas M.E., and Karageorgopoulos D.E. Clinical Microbiology and Infectious Diseases (ECCMID) - 18th European Congress. Drug resistance among Gram-negative and Gram-positive bacteria. IDrugs 11 (2008) 409-411
18. Valverde A., Coque T.M., Garcia-San Miguel L., Baquero F., and Canton R. Complex molecular epidemiology of extended-spectrum beta-lactamases in Klebsiella pneumoniae: a long-term perspective from a single institution in Madrid. J Antimicrob Chemother 61 (2008) 64-72
19. Nicolas-Chanoine M.H., and Jarlier V. Extended-spectrum beta-lactamases in long-term-care facilities. Clin Microbiol Infect 14 Suppl. 1 (2008) 111-116
20. Rodriguez-Bano J., Navarro M.D., Romero L., et al. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis 42 (2006) 37-45
21. Pfaller M.A., and Segreti J. Overview of the epidemiological profile and laboratory detection of extended-spectrum beta-lactamases. Clin Infect Dis 42 Suppl. 4 (2006) S153-S163
22. Schwaber M.J., and Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 60 (2007) 913-920
23. Karageorgopoulos D.E., and Falagas M.E. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 8 (2008) 751-762
24. Matthaiou D.K., Michalopoulos A., Rafailidis P.I., et al. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med 36 (2008) 807-811
25. Kim J.Y., Sohn J.W., Park D.W., Yoon Y.K., Kim Y.M., and Kim M.J. Control of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae using a computer-assisted management program to restrict third-generation cephalosporin use. J Antimicrob Chemother 62 (2008) 416-421
26. Peterson L.R. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam. Clin Microbiol Infect 14 Suppl. 1 (2008) 181-184
27. Falagas M.E., Rafailidis P.I., Kofteridis D., et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother 60 (2007) 1124-1130
28. Bin C., Hui W., Renyuan Z., et al. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis 56 (2006) 351-357
29. Goethaert K., Van Looveren M., Lammens C., et al. High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients. Clin Microbiol Infect 12 (2006) 56-62
30. Zanetti G., Bally F., Greub G., et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 47 (2003) 3442-3447
31. Paterson D.L., Ko W.C., Von Gottberg A., et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 39 (2001) 2206-2212
32. Wong-Beringer A., Hindler J., Loeloff M., et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 34 (2002) 135-146
33. Bush K., Macalintal C., Rasmussen B.A., Lee V.J., and Yang Y. Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Antimicrob Agents Chemother 37 (1993) 851-858
34. Payne D.J., Cramp R., Winstanley D.J., and Knowles D.J. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases. Antimicrob Agents Chemother 38 (1994) 767-772
35. Burgess D.S., Hall II R.G., Lewis II J.S., Jorgensen J.H., and Patterson J.E. Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period. Pharmacotherapy 23 (2003) 1232-1237
36. Ambrose P.G., Bhavnani S.M., and Jones R.N. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program. Antimicrob Agents Chemother 47 (2003) 1643-1646
37. Falagas M.E., Polemis M., Alexiou V.G., Marini-Mastrogiannaki A., Kremastinou J., and Vatopoulos A.C. Antimicrobial resistance of Esherichia coli urinary isolates from primary care patients in Greece. Med Sci Monit 14 (2008) CR75-CR79
38. Lee C.H., Su L.H., Tang Y.F., and Liu J.W. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. J Antimicrob Chemother 58 (2006) 1074-1077
39. Lee C.H., Chu C., Liu J.W., Chen Y.S., Chiu C.J., and Su L.H. Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases. J Antimicrob Chemother 60 (2007) 410-413
40. Endimiani A., Luzzaro F., Perilli M., et al. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis 38 (2004) 243-251
41. Paterson D.L., Ko W.C., Von Gottberg A., et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 39 (2004) 31-37
42. Bassetti M., Righi E., Fasce R., et al. Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing organisms in an intensive care unit. J Antimicrob Chemother 60 (2007) 433-435
43. Kim B.N., Woo J.H., Kim M.N., Ryu J., and Kim Y.S. Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia. J Hosp Infect 52 (2002) 99-106
44. Kang C.I., Kim S.H., Park W.B., et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 48 (2004) 4574-4581
45. Falagas M.E., Karageorgopoulos D.E., and Dimopoulos G. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. Curr Drug Metab 10 (2009) 13-21
46. Kelesidis T., Karageorgopoulos D.E., Kelesidis I., and Falagas M.E. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 62 (2008) 895-904
47. Gales A.C., Jones R.N., and Sader H.S. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect 12 (2006) 315-321
48. Falagas M.E., Kanellopoulou M.D., Karageorgopoulos D.E., et al. Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. Eur J Clin Microbiol Infect Dis 27 (2008) 439-443
49. Falagas M.E., Giannopoulou K.P., Kokolakis G.N., and Rafailidis P.I. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 46 (2008) 1069-1077
50. Garau J. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect 14 Suppl. 1 (2008) 198-202
51. Livermore D.M. Defining an extended-spectrum beta-lactamase. Clin Microbiol Infect 14 Suppl. 1 (2008) 3-10
52. Giske C.G., Sundsfjord A.S., Kahlmeter G., et al. Redefining extended-spectrum beta-lactamases: balancing science and clinical need. J Antimicrob Chemother 63 (2009) 1-4